Tag: Dana-Farber Cancer Institute

Arthur T. Sands, MD, PhD, President and Chief Executive Officer, Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients

September 10, 2010

Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032).  The trial has been given Fast Track status in the U.S. and …

READ MORE
Clinical Trials RSS logo

Clinical Trials Resources for Carcinoid Cancer & Neuroendocrine Tumor Patients

June 13, 2010

Carcinoid and neuroendocrine tumor patients can have the latest information about clinical trials delivered directly to their computers – by RSS feed or e-mail.  Go to https://clinicaltrials.gov/, in the search field enter the type of trial you are…

READ MORE